Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?

References

• AbramsPCardozoLFallMThe standardisation of terminology of lower urinary tract function: report from the Standardisation sub-Committee of the International Continence SocietyNeurourol Urodyn200221216717811857671
   PubMed Web of Science ®Google Scholar
• DrakeMJDo we need a new definition of the overactive bladder syndrome? ICI-RS 2013Neurourol Urodyn201433562262424838519
   PubMed Web of Science ®Google Scholar
• IrwinDEKoppZSAgatepBMilsomIAbramsPWorldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstructionBJU Int201110871132113821231991
   PubMed Web of Science ®Google Scholar
• AbramsPKelleherCJKerrLARogersRGOveractive bladder significantly affects quality of lifeAm J Manag Care2000611 SupplS580S59011183901
   PubMed Web of Science ®Google Scholar
• BrownJSMcGhanWFChokrovertySComorbidities associated with overactive bladderAm J Manag Care2000611 SupplS574S57911183900
   PubMed Web of Science ®Google Scholar
• BurkhardFCBoschJLCruzFUrinary incontinence [guidelines]2017 Available from: https://uroweb.org/guideline/urinary-incontinenceAccessed July 4, 2017
   Google Scholar
• Toviaz (fesoterodine fumarate) [prescribing information]2016 Available from: http://www.medicines.org.uk/emc/medicine/20928Accessed July 4, 2017
   Google Scholar
• de RidderDRoumeguèreTKaufmanLOveractive bladder symptoms, stress urinary incontinence and associated bother in women aged 40 and above: a Belgian epidemiological surveyInt J Clin Pract201367319820423409688
   PubMed Web of Science ®Google Scholar
• AgarwalAEryuzluLNCartwrightRWhat is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and womenEur Urol20146561211121724486308
   PubMed Web of Science ®Google Scholar
• CoyneKSSextonCCIrwinDEKoppZSKelleherCJMilsomIThe impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC studyBJU Int2008101111388139518454794
   PubMed Web of Science ®Google Scholar
• CoyneKSSextonCCClemensJQThe impact of OAB on physical activity in the United States: results from OAB-POLLUrology201382479980623953610
   PubMed Web of Science ®Google Scholar
• TaylorJMcGrotherCWHarrisonSCAssassaPRLower urinary tract symptoms and related help-seeking behaviour in South Asian men living in the UKBJU Int200698360560916925760
   PubMed Web of Science ®Google Scholar
• HeidlerSMertCTemmlCMadersbacherSThe natural history of the overactive bladder syndrome in females: a long-term analysis of a health screening projectNeurourol Urodyn20113081437144121661037
   PubMed Web of Science ®Google Scholar
• EapenRSRadomskiSBGender differences in overactive bladderCan J Urol201623Suppl 12926924589
   PubMedGoogle Scholar
• TettamantiGIliadouANPedersenNLBelloccoRAltmanDAssociation between gestational diabetes mellitus and subsequent overactive bladder among premenopausal female twinsBJOG2013120101289129523647812
   PubMed Web of Science ®Google Scholar
• BunnFKirbyMPinkneyEIs there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studiesInt J Clin Pract201569219921725495905
   PubMed Web of Science ®Google Scholar
• de BoerTASlieker-ten HoveMCBurgerCWVierhoutMEThe prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female populationInt Urogynecol J201122556957521104400
   PubMed Web of Science ®Google Scholar
• PortmanDJGassMLGenitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause SocietyMaturitas201479334935425179577
   PubMed Web of Science ®Google Scholar
• IosifCSBekassyZPrevalence of genito-urinary symptoms in the late menopauseActa Obstet Gynecol Scand19846332572606730943
   PubMed Web of Science ®Google Scholar
• BlakemanPJHiltonPBulmerJNOestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen statusBJU Int2000861323810886079
   PubMed Web of Science ®Google Scholar
• PalmaFVolpeAVillaPCagnacciAVaginal atrophy of women in postmenopause: results from a multicentric observational study – the AGATA studyMaturitas201683404426421474
   PubMed Web of Science ®Google Scholar
• JuliatoCRBaccaroLFPedroAOCosta-PaivaLLui-FilhoJPinto-NetoAMSubjective urinary urgency in middle age women: a population-based studyMaturitas201685828726857885
   PubMed Web of Science ®Google Scholar
• RobinsonDToozs-HobsonPCardozoLThe effect of hormones on the lower urinary tractMenopause Int201319415516224336244
   PubMedGoogle Scholar
• Calleja-AgiusJBrincatMPThe urogenital system and the menopauseClimacteric201518Suppl 1182226366796
   PubMed Web of Science ®Google Scholar
• LethabyAAyelekeRORobertsHLocal oestrogen for vaginal atrophy in postmenopausal womenCochrane Database Syst Rev20168CD00150027577677
   PubMed Web of Science ®Google Scholar
• BuchholzSMögeleMLintermansAVaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancerClimacteric201518225225925427450
   PubMed Web of Science ®Google Scholar
• ChughtaiBFordeJCBuckJThe concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal womenPost Reprod Health2016221344026883688
   PubMedGoogle Scholar
• ChuCMHarvieHSSmithALAryaLAAndyUUThe impact of treatment of overactive bladder on physical activity limitationsJ Womens Health (Larchmt)201625880180527135856
   PubMed Web of Science ®Google Scholar
• RantellACardozoLKhullarVPersonal goals and expectations of OAB patients in the UKNeurourol Urodyn20173641194120027564470
   PubMed Web of Science ®Google Scholar
• LampelaPPaajanenTHartikainenSHuupponenRCentral anticholinergic adverse effects and their measurementDrugs Aging2015321296397426518014
   PubMed Web of Science ®Google Scholar
• ChancellorMBooneTAnticholinergics for overactive bladder therapy: central nervous system effectsCNS Neurosci Ther201218216717422070184
   PubMed Web of Science ®Google Scholar
• LampelaPTaipaleHHartikainenSAssociation between anticholinergic load and frailty in community-dwelling older peopleJ Am Geriatr Soc201664367167227000355
   PubMed Web of Science ®Google Scholar
• CetinelBOnalBRationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effectsKorean J Urol2013541280681524363860
   PubMedGoogle Scholar
• ChancellorMBStaskinDRKayGGSandageBWOefeleinMGTsaoJWBlood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladderDrugs Aging201229425927322390261
   PubMed Web of Science ®Google Scholar
• HawkinsRAO’KaneRLSimpsonIAViñaJRStructure of the blood-brain barrier and its role in the transport of amino acidsJ Nutr20061361 Suppl218S226S16365086
   PubMed Web of Science ®Google Scholar
• GellerEJCraneAKWellsECEffect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal womenClin Drug Investig20123210697705
   PubMed Web of Science ®Google Scholar
• ScheifeRTakedaMCentral nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderlyClin Ther200527214415315811477
   PubMed Web of Science ®Google Scholar
• KerdraonJRobainGJeandelCImpact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderlyProg Urol2014241167268125214448
   PubMed Web of Science ®Google Scholar
• ZeeviNPachterJMcCulloughLDWolfsonLKuchelGAThe blood-brain barrier: geriatric relevance of a critical brain-body interfaceJ Am Geriatr Soc20105891749175720863334
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory AgencyPublic assessment report – mutual recognition procedure: Mictonorm XL 45 mg modified release capsules (propiverine hydrochloride)2011 Available from: http://www.mhra.gov.uk/home/groups/par/documents/websitere-sources/con143796.pdfAccessed July 4, 2017
   Google Scholar
• WaggAVerdejoCMolanderUReview of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladderInt J Clin Pract20106491279128620529135
   PubMed Web of Science ®Google Scholar
• MalhotraBGandelmanKSachseRWoodNMichelMCThe design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodineCurr Med Chem200916334481448919835561
   PubMed Web of Science ®Google Scholar
• KayGGMaruffPScholfieldDEvaluation of cognitive function in healthy older subjects treated with fesoterodinePostgrad Med20121243715
   PubMed Web of Science ®Google Scholar
• DubeauCEKrausSRGrieblingTLEffect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trialJ Urol2014191239540423973522
   PubMed Web of Science ®Google Scholar
• ErdemNChuFMManagement of overactive bladder and urge urinary incontinence in the elderly patientAm J Med20061193 Suppl 1293616483866
   PubMed Web of Science ®Google Scholar
• Lechevallier-MichelNMolimardMDartiguesJFFabrigouleCFourrier-RéglatADrugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID studyBr J Clin Pharmacol200559214315115676035
   PubMed Web of Science ®Google Scholar
• NakagawaHNiuKHozawaAImpact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort studyJ Urol201018441413141820727545
   PubMed Web of Science ®Google Scholar
• BrownJSVittinghoffEWymanJFUrinary incontinence: does it increase risk for falls and fractures?Am Geriatr Soc2000487721725
   PubMed Web of Science ®Google Scholar
• NuotioMTammelaTLLuukkaalaTJylhäMUrgency and urge incontinence in an older population: ten-year changes and their association with mortalityAging Clin Exp Res200214541241912602577
   PubMed Web of Science ®Google Scholar
• LeeLKGorenAZouKHPotential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladderInt J Clin Pract2016701668126662296
   PubMed Web of Science ®Google Scholar
• CardozoLKhullarVWangJTGuanZSandPKFesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?BJU Int2010106681682120151972
   PubMed Web of Science ®Google Scholar
• García-BaqueroRMadurgaBGarcíaMVFernándezMARosetyJMÁlvarez-OssorioJLNew perspectives of treatment with fesoterodine fumarate in patients with overactive bladderActas Urol Esp20133728391 Spanish23374672
   PubMed Web of Science ®Google Scholar
• KhullarVRovnerESDmochowskiRNittiVWangJGuanZFesoterodine dose response in subjects with overactive bladder syndromeUrology200871583984318342923
   PubMed Web of Science ®Google Scholar
• AbramsPAnderssonKEMuscarinic receptor antagonists for overactive bladderBJU Int20071005987100617922784
   PubMed Web of Science ®Google Scholar
• SellersDJChess-WilliamsRMuscarinic agonists and antagonists: effects on the urinary bladderHandb Exp Pharmacol201220837540022222707
   PubMedGoogle Scholar
• ChappleCRMuscarinic receptor antagonists in the treatment of overactive bladderUrology2000555A Suppl334610767450
   PubMed Web of Science ®Google Scholar
• WaggAKhullarVMarschall-KehrelDFlexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trialJ Am Geriatr Soc201361218519323350833
   PubMed Web of Science ®Google Scholar
• WaggAKhullarVMichelMCOelkeMDarekarABitounCELong-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trialNeurourol Urodyn201433110611423460503
   PubMed Web of Science ®Google Scholar
• BulchandaniSToozs-HobsonPParsonsMMcCootySPerkinsKLatthePEffect of anticholinergics on the overactive bladder and bowel domain of the electronic personal assessment questionnaire (ePAQ)Int Urogynecol J2015264533725323310
   PubMed Web of Science ®Google Scholar
• KrausSRRuiz-CerdáJLMartireDWangJTWaggASEfficacy and tolerability of fesoterodine in older and younger subjects with overactive bladderUrology20107661350135720974482
   PubMed Web of Science ®Google Scholar
• OelkeMBecherKCastro-DiazDAppropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014)Age Ageing201544574575526104505
   PubMed Web of Science ®Google Scholar
• QinLLuoXZouKHSnedecorSJEconomic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United StatesJ Med Econ201619322923526488196
   PubMed Web of Science ®Google Scholar
• RoccaMAAmatoMPDe StefanoNClinical and imaging assessment of cognitive dysfunction in multiple sclerosisLancet Neurol201514330231725662900
   PubMed Web of Science ®Google Scholar
• Perez-LloretSPeraltaMCBarrantesFJPharmacotherapies for Parkinson’s disease symptoms related to cholinergic degenerationExpert Opin Pharmacother201617182405241527785919
   PubMed Web of Science ®Google Scholar
• WeissbartSJLewisRSmithALHarvieHSMillerJMAryaLAImpact of dry mouth on fluid intake and overactive bladder symptoms in women taking fesoterodineJ Urol201619551517152226682757
   PubMed Web of Science ®Google Scholar
• Holtzer-GoorKMGaultneyJGvan HoutenPCost-effectiveness of including a nurse specialist in the treatment of urinary incontinence in primary care in the NetherlandsPLoS One20151010e013822526426124
   PubMed Web of Science ®Google Scholar
• ChappleCOelkeMKaplanSAScholfieldDArumiDWaggASFesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic reviewCurr Med Res Opin20153161201124325798911
   PubMed Web of Science ®Google Scholar
• SyanRBruckerBMGuideline of guidelines: urinary incontinenceBJU Int20161171203326033093
   PubMed Web of Science ®Google Scholar